Gamze Özkan

Gamze Özkan

Auto-generated profile, based on publicly available information

Gamze Özkan

Marmara University School of Medicine

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2021 in International Ophthalmology
Verified
Journal Article
Closed access
PDF file
MSMehmet Orkun Sevik
Mehmet Orkun Sevik
AAAslan Aykut
Aslan Aykut
GÖGamze Özkan
Gamze Özkan
VDVolkan Dericioğlu
Volkan Dericioğlu
ÖŞÖzlem Şahin
Özlem Şahin

1 November 2022 in EXPLORE
Verified
Journal Article
Closed access
BDBerna Dincer
Berna Dincer
DIDemet İnAngil
Demet İnAngil
GIGökhan İnAngil
Gökhan İnAngil
NBNefise Bahçecik
Nefise Bahçecik
EAElif Yıldırım Ayaz
Elif Yıldırım Ayaz
GÖGamze Özkan
Gamze Özkan

29 March 2025 in BMJ Open Ophthalmology
Verified
Journal Article
Open access
PDF file
GÖGamze Özkan
Gamze Özkan
STSemra Akkaya Turhan
Semra Akkaya Turhan
ETEbru Toker
Ebru Toker
Objective: To assess the impact of eye drops containing high molecular weight hyaluronic acid (HMW-HA) and low molecular weight hyaluronic acid (LMW-HA) on corneal nerve regeneration, dendritic cell (DC) density, corneal sensitivity (CS) and ocular surface parameters in patients with keratoconus following corneal crosslinking (CXL). Methods and analysis: 63 eyes of 55 patients with keratoconus were randomised to receive eye drops containing HMW-HA (n: 20) for 12 months, LMW-HA (n: 23) for 12 months and polyvinyl alcohol (n: 20) until closure of the epithelial defect in the control group after CXL. Subbasal nerve plexus (SNP) was imaged with corneal confocal microscopy and quantified with ACCMetrics. DC density was calculated with Image J. Ocular Surface Disease Index (OSDI) questionnaire and non-invasive break-up time (NI-TBUT) were evaluated. All measurements were performed before CXL and 1, 3, 6 and 12 months postsurgery. Results: At 6 months post-CXL, SNP reached to its preoperative. CS was higher in the HMW-HA groups compared with the other two groups in the 3rd and 6th month post-CXL. DC density was higher in the LMW-HA group compared with the HMW-HA group in the postoperative 3rd month. OSDI were higher in the control group compared with both the LMW-HA and HMW-HA groups at postoperative 3rd and 6th months. NI-TBUT was lower in the control group in the 6th and 12th months compared with the other groups. Conclusions: The use of artificial tear drops containing HMW-HA may have a therapeutic effect to promote corneal nerve regrowth and support faster functional recovery after CXL. Trial registration number: NCT06243991 .

26 August 2025 in Ocular Immunology and Inflammation
Verified
Journal Article
Closed access
GÖGamze Özkan
Gamze Özkan
GGGizem Doğan Gökçe
Gizem Doğan Gökçe
STSemra Akkaya Turhan
Semra Akkaya Turhan
To evaluate the clinical presentations, visual outcomes, meibography, and non-invasive tear break-up time (NIBUT) findings in pediatric ocular rosacea (OR) patients receiving maintenance therapy with topical cyclosporine. This retrospective study reviewed medical records of patients under 16 years diagnosed with OR. Demographic characteristics, corneal involvement, delayed diagnosis, and recurrence rates were assessed. Best-corrected visual acuity (BCVA), cylindrical value, meibography findings, and NIBUT were evaluated at presentation and the final visit. During the acute phase, all patients received artificial tear, topical antibiotic, topical steroid, and systemic azithromycin. For maintenance therapy, topical 0.05% cyclosporine drops were used. There were 22 patients with a mean age of 7.6 ± 3.4 years. The mean follow-up time was 23.8 ± 9.9 months. Seven patients had skin involvement. Corneal involvement with was present in 20 out of 22 patients. Delayed diagnosis was present in 10 patients, with a mean delay duration of 10.0 ± 2.7 months. Two patients showed recurrence and mean recurrence time was 6.50 ± 2.50 months. The BCVA of eyes with poorer vision improved compared to the initial presentation (0.34 ± 0.27 logMAR) at the last visit (0.02 ± 0.04 logMAR). The cylindrical value of the eyes with poorer vision decreased at the last visit (-2.21 ± 1.33 D) compared to baseline. The rate of MG loss in both upper and lower eyelids decreased with treatment and NIBUT improved. This retrospective case series suggests that long-term maintenance therapy with topical cyclosporine, improves visual outcomes, reduces ocular surface inflammation and stabilizes the tear film in pediatric patients with OR.

30 November 2025 in Eye
Verified
Journal Article
Closed access
PDF file
BKBetul Kubat
Betul Kubat
GOGamze Ozkan
Gamze Ozkan
CSCanan Sanal-Toprak
Canan Sanal-Toprak
MDMerve Demirci
Merve Demirci
STSemra Akkaya Turhan
Semra Akkaya Turhan

1 January 2024 in Beyoglu Eye Journal
Verified
Journal Article
Open access
GOGamze Ozkan
Gamze Ozkan
STSemra Akkaya Turhan
Semra Akkaya Turhan
The objective of the study was to evaluate the changes in the meibomian glands (MGs) and ocular surface parameters after corneal cross-linking (CXL) in keratoconus patients. Forty-eight eyes of 48 keratoconus patients that underwent epi-off CXL were included in this prospective study. Upper and lower lid MGs were assessed with non-contact meibography at preoperatively, 1st, 3rd, 6th, and 12th month after CXL. Uncorrected distance visual acuity (UCVA), corrected distance visual acuity (BCVA), spherical equivalent (SE), and corneal tomography findings (K1, K2, Kmean, and Kmax) were recorded at each visit. Ocular surface staining score (Oxford grade), ocular surface disease index (OSDI) questionnaire, and non-invasive tear break-up time (NI-TBUT) were evaluated at preoperatively and 12 months after CXL. K1, K2, Kmean, and Kmax were decreased at post-operative 12th month compared to baseline (p=0.004, p<0.001, p<0.001, and p<0.001, respectively). UCVA, BCVA, and SE did not change between preoperatively and post-operative 12 months (p=0.142, p=0.306, and p=1.000, respectively). NI-TBUT showed similarity between pre-operative and 12 months values (p=0.180), while OSDI scores significantly decreased (p<0.001). MG loss in the upper and lower lids did not show significant difference compared to pre-operative values at any of the follow-up visits (p=0.121 and p=0.117, respectively). CXL treatment did not significantly affect the NI-TBUT and MGs morphology, while improving ocular symptoms.